Acute Respiratory Distress Syndrome – Cannabis Research

Acute Respiratory Distress Syndrome Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 17 studies associated with Acute Respiratory Distress Syndrome.

Here is a small sampling of Acute Respiratory Distress Syndrome studies by title:

Components of the Acute Respiratory Distress Syndrome Research Dashboard

  • Dosing information available for Acute Respiratory Distress Syndrome
  • Chemotype guidance for treating Acute Respiratory Distress Syndrome with cannabis
  • Synopsis of cannabis research for Acute Respiratory Distress Syndrome
  • Individual study details for Acute Respiratory Distress Syndrome

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Acute Respiratory Distress Syndrome

Description of Acute Respiratory Distress Syndrome

Acute lung injury (ALI) and it's more severe form, the acute respiratory distress syndrome (ARDS) are severe and potentially life-threatening complication that can be causes by a variety of underlying pathologies such as trauma (e.g. surgery, aspiration), bacterial and viral infections (e.g. Staphylococcus aureus or COVID-19 respectively), inhalation exposure to toxins, or contributing conditions (e.g. shock, sepsis, burn injuries, EVALI) for example.

Developing ARDS is associated with significant mortality rates, which are worse in vulnerable populations such as people with lowered immunity. Infection, shock, or trauma to the lungs induce the activation of excessive numbers of T-cells leading to an acute fluid build-up (edema) in the interstitial and alveolar tissues of the lungs, which in turn can progress to cytokine storm syndrome and subsequent severe injuries to the lung and death.

Disease Classification

Condition: Acute Respiratory Distress Syndrome
Disease Family:
Organ System: Respiratory System
ICD-10 Chapter: Diseases of the Respiratory System
ICD-10 Code: J80

Acute Respiratory Distress Syndrome Symptoms:

Shortness of breath (can be severe), tachypnea (rapid, labored beathing), painful respiration, chest pains, hypoxiema (low concentration of blood oxygen), tachycardia (rapid heart rate), confusion, altered level of consciousness, feeling tired or exhausted, pale, sweaty skin, blueish hue to lips or fingernails, hypotension (low blood pressure), wet (crackling) lung sounds, productive cough, production of phlegm, and resulting complications such as fever, sepsis, atelectasis (alveoli i.e. the small air pockets in the lung collapse), pulmonary hypertension, hypertension, blood clots, organ failure, respiratory arrest and death.

Also known as:

Acute lung injury (ALI), Acute Respiratory Distress Syndrome (ARDS), Acute respiratory distress, Adult respiratory distress syndrome, E-cigarette or vaping use-associated lung injury (EVALI), Vaping-associated pulmonary injury (VAPI)

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.